278 related articles for article (PubMed ID: 11310835)
1. The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies.
Schultz H; Weiss J; Carroll SF; Gross WL
J Leukoc Biol; 2001 Apr; 69(4):505-12. PubMed ID: 11310835
[TBL] [Abstract][Full Text] [Related]
2. From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI).
Schultz H
Autoimmun Rev; 2007 Mar; 6(4):223-7. PubMed ID: 17317612
[TBL] [Abstract][Full Text] [Related]
3. BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro.
Schultz H; Schinke S; Mosler K; Herlyn K; Schuster A; Gross WL
Pediatr Pulmonol; 2004 Feb; 37(2):158-64. PubMed ID: 14730661
[TBL] [Abstract][Full Text] [Related]
4. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis.
Dorlöchter L; Carlsson M; Olafsdottir EJ; Røksund OD; Rosendahl K; Fluge G
J Cyst Fibros; 2004 Aug; 3(3):179-83. PubMed ID: 15463905
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis.
Carlsson M; Eriksson L; Pressler T; Kornfält R; Mared L; Meyer P; Wiik A; Wieslander J; Segelmark M
J Cyst Fibros; 2007 May; 6(3):228-33. PubMed ID: 17166780
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal/permeability-increasing protein antineutrophil cytoplasmic antibodies (ANCA) and associated diseases: clinical relevance of an emerging ANCA target antigen.
Emmi L; Chatzipetrou A
Ann Ital Med Int; 2005; 20(4):205-8. PubMed ID: 16610250
[No Abstract] [Full Text] [Related]
7. Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis.
Sedivá A; Bartůnková J; Kolárová I; Hrusák O; Vávrová V; Macek M; Lockwood CM; Dunn AC
J Autoimmun; 1998 Apr; 11(2):185-90. PubMed ID: 9650098
[TBL] [Abstract][Full Text] [Related]
8. Antineutrophil cytoplasmic autoantibodies in patients with systemic lupus erythematosus recognize a novel 69 kDa target antigen of neutrophil granules.
Chen M; Zhao MH; Zhang YK; Wang HY
Nephrology (Carlton); 2005 Oct; 10(5):491-5. PubMed ID: 16221101
[TBL] [Abstract][Full Text] [Related]
9. Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis.
Khanna D; Aggarwal A; Bhakuni DS; Dayal R; Misra R
J Rheumatol; 2003 Jun; 30(6):1248-52. PubMed ID: 12784398
[TBL] [Abstract][Full Text] [Related]
10. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.
Schultz H; Csernok E; Schuster A; Schmitz TS; Ernst M; Gross WL
Pediatr Allergy Immunol; 2000 May; 11(2):64-70. PubMed ID: 10893006
[TBL] [Abstract][Full Text] [Related]
11. Prospects for use of recombinant BPI in the treatment of gram-negative bacterial infections.
Elsbach P; Weiss J
Infect Agents Dis; 1995 Jun; 4(2):102-9. PubMed ID: 7613727
[TBL] [Abstract][Full Text] [Related]
12. BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections.
Schultz H; Schinke S; Weiss J; Cerundolo V; Gross WL; Gadola S
Clin Exp Immunol; 2003 Aug; 133(2):252-9. PubMed ID: 12869032
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins.
Levy O; Ooi CE; Elsbach P; Doerfler ME; Lehrer RI; Weiss J
J Immunol; 1995 May; 154(10):5403-10. PubMed ID: 7730641
[TBL] [Abstract][Full Text] [Related]
14. A peptide derived from human bactericidal/permeability-increasing protein (BPI) exerts bactericidal activity against Gram-negative bacterial isolates obtained from clinical cases of bovine mastitis.
Chockalingam A; McKinney CE; Rinaldi M; Zarlenga DS; Bannerman DD
Vet Microbiol; 2007 Nov; 125(1-2):80-90. PubMed ID: 17560054
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin.
Rotschild M; Elias N; Berkowitz D; Pollak S; Shinawi M; Beck R; Bentur L
Clin Exp Med; 2005 Jul; 5(2):80-5. PubMed ID: 16096858
[TBL] [Abstract][Full Text] [Related]
16. Preferential binding of the neutrophil cytoplasmic granule-derived bactericidal/permeability increasing protein to target bacteria. Implications and use as a means of purification.
Mannion BA; Kalatzis ES; Weiss J; Elsbach P
J Immunol; 1989 Apr; 142(8):2807-12. PubMed ID: 2539411
[TBL] [Abstract][Full Text] [Related]
17. Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.
Aichele D; Schnare M; Saake M; Röllinghoff M; Gessner A
Infect Immun; 2006 Aug; 74(8):4708-14. PubMed ID: 16861658
[TBL] [Abstract][Full Text] [Related]
18. Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders.
Stoffel MP; Csernok E; Herzberg C; Johnson T; Carroll SF; Gross WL
Clin Exp Immunol; 1996 Apr; 104(1):54-9. PubMed ID: 8603534
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis.
Zhao MH; Jones SJ; Lockwood CM
Clin Exp Immunol; 1995 Jan; 99(1):49-56. PubMed ID: 7813109
[TBL] [Abstract][Full Text] [Related]
20. The bactericidal/permeability increasing protein of neutrophils is a potent antibacterial and anti-endotoxin agent in vitro and in vivo.
Elsbach P; Weiss J; Doerfler M; Shu C; Kohn F; Ammons WS; Kung AH; Meszaros KK; Parent JB
Prog Clin Biol Res; 1994; 388():41-51. PubMed ID: 7831373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
